Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
KANSAS CITY, Kan. and BOSTON, Mass., Feb. 12, 2013 /PRNewswire/ -- Aratana Therapeutics, a biopharmaceutical company developing innovative medicines for cats and dogs (companion animals), today announced it has appointed Don Stitzenberg as Vice President of Manufacturing and Tammy Newbold as Vice President of Chemistry, Manufacturing and Controls. Don and Tammy are both seasoned veterans in the animal health industry and are valuable additions to Aratana's growing team of experts.
Ernst Heinen, DVM, Ph.D., Head of Aratana's Drug Evaluation and Development, stated, "We believe success is contingent on assembling the strongest possible team with proven expertise in all aspects of clinical and commercial drug development. For this reason, we are very pleased to welcome Don and Tammy to Aratana, each of whom are proven experts in establishing and executing quality development and manufacturing programs for animal health drugs."
Prior to joining Aratana, Mr. Stitzenberg founded Carnegie Business Associates, an international supply chain consulting company, specializing in the pharmaceutical, chemical and cosmetics industries. He spent 33 years in executive positions at Merck and Co., Inc. in marketing, research, planning and manufacturing. He was Executive Director of Planning for Merck where he led the formation of Merck AgVet, Merck's Animal Health Division. Additionally, he negotiated the formation of Merial Inc., a global animal health joint venture with Rhone Merieux (now Sanofi).
Mr. Stitzenberg holds a BS in mathematics from Carnegie Mellon University where he is a Life Member of the Carnegie Mellon Board of Trustees. He also holds an MBA and an LLB and is a Member of the New Jersey Bar Association.
Prior to joining Aratana, Ms. Newbold founded Ceris Consulting, which provides Chemistry, Manufacturing and Controls guidance to animal health companies seeking FDA approval of products. Ms. Newbold led the Worldwide Regulatory Chemistry, Manufacturing and Controls group at Merial, Inc. Her team identified worldwide regulatory requirements to define CMC for product development and also prepared worldwide pharmaceutical regulatory dossiers. She was an Associate Manager of Regulatory Affairs at Merck & Co., Inc. where she helped define worldwide CMC regulations for animal health products. Ms. Newbold served as a Process Development Scientist at Bausch & Lomb where she was in charge of manufacturing processes and facilities.
Ms. Newbold earned her B.S. Degree in Biochemistry from the State University of New York at Stonybrook in 1986.
About Aratana Therapeutics
Aratana Therapeutics is a biopharmaceutical company positioned to deliver high quality new medicines that address significant therapeutic needs for cats and dogs (companion animals). Aratana licenses and develops proprietary, patent-protected compounds acquired from human pharmaceutical and biotechnology companies and then develops strategies to maximize the value of the programs for the animal health market. For more information, please visit www.aratanatherapeutics.com.